{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:40:07Z","timestamp":1781890807257,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10067-019-04762-4","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T11:12:18Z","timestamp":1567509138000},"page":"3669-3676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Optimisation of botulinum toxin type a treatment for the management of Raynaud\u2019s phenomenon using a dorsal approach: a prospective case series"],"prefix":"10.1007","volume":"38","author":[{"given":"Kiran","family":"Dhaliwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2027-547X","authenticated-orcid":false,"given":"Michelle F.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"4762_CR1","doi-asserted-by":"crossref","unstructured":"Flavahan NA (2015) Pathophysiological regulation of the cutaneous vascular system in Raynaud\u2019s phenomenon. Raynaud\u2019s Phenomenon: Springer, pp 57\u201379","DOI":"10.1007\/978-1-4939-1526-2_5"},{"key":"4762_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/1753193413516242","volume":"39","author":"L Uppal","year":"2014","unstructured":"Uppal L, Dhaliwal K, Butler P (2014) A prospective study of the use of botulinum toxin injections in the treatment of Raynaud\u2019s syndrome associated with systemic sclerosis. J Hand Surg Eur Vol 39:876\u2013880","journal-title":"J Hand Surg Eur Vol"},{"key":"4762_CR3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/bmj.301.6752.590","volume":"301","author":"A Silman","year":"1990","unstructured":"Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud\u2019s phenomenon in general practice. BMJ 301:590\u2013592","journal-title":"BMJ"},{"key":"4762_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0950-821X(88)80070-7","volume":"2","author":"J De Trafford","year":"1988","unstructured":"De Trafford J, Lafferty K, Potter C et al (1988) An epidemiological survey of Raynaud\u2019s phenomenon. Eur J Vasc Surg 2:167\u2013170","journal-title":"Eur J Vasc Surg"},{"key":"4762_CR5","doi-asserted-by":"crossref","unstructured":"Iorio ML, Masden DL, Higgins JP, editors (2012) Botulinum toxin A treatment of Raynaud's phenomenon: a review. Seminars in arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2011.07.006"},{"key":"4762_CR6","unstructured":"Ong VH, Denton CP (2015) Secondary Raynaud\u2019s phenomenon. Raynaud\u2019s Phenomenon: Springer, pp 107\u201327"},{"key":"4762_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.7326\/0003-4819-139-10-200311180-00030","volume":"139","author":"S Rosenkranz","year":"2003","unstructured":"Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with systemic sclerosis-associated lung fibrosis and the raynaud phenomenon. Ann Intern Med 139:871\u2013873","journal-title":"Ann Intern Med"},{"key":"4762_CR8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/art.24351","volume":"60","author":"L Chung","year":"2009","unstructured":"Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon: a randomized, controlled trial. Arthritis Rheum 60:870\u2013877","journal-title":"Arthritis Rheum"},{"key":"4762_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/VHRM.S4551","volume":"6","author":"TL Levien","year":"2010","unstructured":"Levien TL (2010) Advances in the treatment of Raynaud\u2019s phenomenon. Vasc Health Risk Manag 6:167\u2013177","journal-title":"Vasc Health Risk Manag"},{"key":"4762_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s40674-014-0006-z","volume":"1","author":"FM Wigley","year":"2015","unstructured":"Wigley FM, Herrick AL (2015) Management of Raynaud\u2019s Phenomenon and digital ulcers. Curr Treat Opt Rheumatol 1:68\u201381","journal-title":"Curr Treat Opt Rheumatol"},{"key":"4762_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jvs.2013.03.012","volume":"57","author":"GJ Landry","year":"2013","unstructured":"Landry GJ (2013) Current medical and surgical management of Raynaud\u2019s syndrome. J Vasc Surg 57:1710\u20131716","journal-title":"J Vasc Surg"},{"key":"4762_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","volume":"34","author":"T Sycha","year":"2004","unstructured":"Sycha T, Graninger M, Auff E, Schnider P (2004) Botulinum toxin in the treatment of Raynaud\u2019s phenomenon: a pilot study. Eur J Clin Investig 34:312\u2013313","journal-title":"Eur J Clin Investig"},{"key":"4762_CR13","first-page":"191","volume":"124","author":"MW Neumeister","year":"2009","unstructured":"Neumeister MW, Chambers CB, Herron MS et al (2009) Botox therapy for ischemic digits. PRS 124:191\u2013201","journal-title":"PRS"},{"key":"4762_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","volume":"34A","author":"A Fregene","year":"2009","unstructured":"Fregene A, Ditmars D, Siddiqui A (2009) Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud\u2019s phenomenon. J Hand Surg Am 34A:446\u2013452","journal-title":"J Hand Surg Am"},{"key":"4762_CR15","first-page":"217","volume":"119","author":"AL Van Beek","year":"2007","unstructured":"Van Beek AL, Lim PK, Gear AJ et al (2007) Management of vasospastic disorders with botulinum toxin A. PRS 119:217\u2013226","journal-title":"PRS"},{"key":"4762_CR16","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","volume":"35A","author":"MW Neumeister","year":"2010","unstructured":"Neumeister MW (2010) Botulinum toxin type A in the treatment of Raynaud\u2019s phenomenon. J Hand Surg Am 35A:2085\u20132092","journal-title":"J Hand Surg Am"},{"key":"4762_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2310\/7750.2008.07044","volume":"12","author":"I Kossintseva","year":"2008","unstructured":"Kossintseva I, Barankin B (2008) Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutan Med Surg 12:189\u2013193","journal-title":"J Cutan Med Surg"},{"key":"4762_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/archdermatol.2011.1144","volume":"148","author":"L Smith","year":"2012","unstructured":"Smith L, Polsky D, Franks AG (2012) Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol 148:426\u2013428","journal-title":"Arch Dermatol"},{"key":"4762_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/ajd.12326","volume":"56","author":"H Zhao","year":"2015","unstructured":"Zhao H, Lian Y (2015) Clinical and image improvement of Raynaud\u2019s phenomenon after botulinum toxin type A treatment. Australas J Dermatol 56:202\u2013205","journal-title":"Australas J Dermatol"},{"key":"4762_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jaad.2013.06.029","volume":"5","author":"SN Jenkins","year":"2013","unstructured":"Jenkins SN, Neyman KM, Veledar E et al (2013) A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon. J Am Acad Dermatol 5:834\u2013835","journal-title":"J Am Acad Dermatol"},{"key":"4762_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10072-015-2084-6","volume":"36","author":"X Zhang","year":"2015","unstructured":"Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y, Jin L (2015) Treatment of Raynaud\u2019s phenomenon with botulinum toxin type A. Neurol Sci 36:1225\u20131231","journal-title":"Neurol Sci"},{"key":"4762_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1346-8138.13030","volume":"43","author":"M Si","year":"2016","unstructured":"Si M, Yamada K, Toki S et al (2016) Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol 43:56\u201362","journal-title":"J Dermatol"},{"key":"4762_CR23","unstructured":"Serri J, Legre R, Veit V, Guardia C, Gay A, editors (2013) [Botulinum toxin type A contribution in the treatment of Raynaud\u2019s phenomenon due to systemic sclerosis]. Annales de chirurgie plastique et esthetique"},{"key":"4762_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/art.40123","volume":"69","author":"RJ Bello","year":"2017","unstructured":"Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD (2017) The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol 69:1661\u20131669","journal-title":"Arthritis Rheumatol"},{"key":"4762_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhsa.2012.01.021","volume":"37A","author":"AV Stone","year":"2012","unstructured":"Stone AV, Koman LA, Callahan MF et al (2012) The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am 37A:795\u2013802","journal-title":"J Hand Surg Am"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04762-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04762-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:32:55Z","timestamp":1599003175000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04762-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4762"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04762-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}